In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Restenosis: Multi-Billion-Dollar Market Tempts Many

This article was originally published in Start Up

Executive Summary

A variety of approaches are being used to combat the problem of restenosis following angioplasty. In addition to separate drug and device efforts, several companies are working on drug-device collaborations to prevent restenosis.

You may also be interested in...

CardioGene Therapeutics

Gene Therapy; Cardiovascular; Restenosis. CardioGene has a patented method of promoting gene expression in vascular smooth muscle cells and endothelial cells. The technology also incorporates a double balloon catheter for delivery of the product to theinner wall of the blood vessel. CardioGene also has nine patent applications that include the use of adenovirus vectors to carry genes to vascular smooth muscle cells and means of coating stents with recombinant DNA.

Illumenex Corp.

Phototherapy; Restenosis. Illumenex is using light-activated psoralen to prevent the neointimal hyperplasia that occurs after balloon angioplasty with or without stent implantation and causes blood vessel restenosis.

Interventional Innovations Corp.

Surgical Devices; Restenosis. Interventional Innovations is targeting restenosis with a minimally invasive catheter-based x-ray therapy which uses soft, or less energized x-rays. Interventional's system consists of an x-ray cetheter, a delivery sheathand a control unit that allows the physician to increase the depth of penetration, making it possible to tailor the radiation to treat a variety of disease states.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts